This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2000;283:46.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved a combination of aspirin and the antiplatelet agent dipyridamole (Aggrenox; Boehringer Ingelheim Pharmaceuticals Inc, Richfield, Conn) to reduce the risk of stroke for patients who have already had transient ischemic attacks or completed ischemic strokes due to blood clots in the brain. Each hard gelatin capsule contains 200 mg of dipyridamole in an extended-release form and 25 mg of aspirin as an immediate-release sugar-coated tablet.

The pivotal clinical trial of the drug was a double-blind, placebo-controlled, 24-month study that included 6602 patients who had an ischemic stroke (76%) or transient ischemic attack (24%) within 3 months before entering the trial. The study compared use of the combination pill with use of each active ingredient alone and with placebo. These comparisons showed that the combination reduced the risk of stroke by 36.8% compared with placebo, 22.1% compared with aspirin alone, and 24.4% compared with dipyridamole alone. The . . . [Full Text of this Article]